TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit fi ...

Core Insights - Nature's Sunshine Products, Inc. reported a strong start to 2025 with first quarter revenue of $113 million, reflecting a 5% increase on a constant currency basis and a 20% rise in adjusted EBITDA to $11 million compared to the previous year [3][8][6] Financial Performance - Net sales increased by 2% to $113.2 million from $111.0 million in the same quarter last year, with a 5% increase when excluding foreign exchange impacts [6][8] - Gross profit margin improved to 72.1% from 71.2% year-over-year, driven by price increases and effective cost-saving initiatives [6] - GAAP net income attributable to common shareholders rose 104% to $4.7 million, or $0.25 per diluted share, compared to $2.3 million, or $0.12 per diluted share, in the prior year [8][12] Segment Performance - Sales by region showed varied performance: - Asia: $48.7 million, up 5.3% (10.1% excluding currency impact) - Europe: $24.1 million, up 8.2% (8.6% excluding currency impact) - North America: $35.0 million, down 4.1% (3.7% excluding currency impact) - Latin America and Other: $5.5 million, down 8.2% (3.7% excluding currency impact) [4][30] Cost Management - Selling, general and administrative expenses (SG&A) decreased slightly to $40.6 million from $40.8 million, representing 35.8% of net sales compared to 36.7% in the prior year [9] - Operating income increased to $6.2 million, or 5.4% of net sales, compared to $4.6 million, or 4.2% of net sales, in the previous year [10] Capital Allocation - The board of directors authorized a share repurchase program of up to $25 million, supplementing the remaining $8.3 million from a previous authorization [2][4] Outlook - The company expects full-year 2025 net sales to range between $445 million and $470 million, with adjusted EBITDA projected between $38 million and $44 million [15]